Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.


a. trombótico-a, rel. a la trombosis o que padece de ella.
English-Spanish Medical Dictionary © Farlex 2012
Mentioned in ?
References in periodicals archive ?
Thrombotic thrombocytopenic purpura (TTP), initially described by Moschcowitz in 1925, is a rare but life-threatening microangiopathy characterized by uncontrolled thrombotic phenomena [1,2].
Group-I comprised of patients who were admitted in Government General Hospital, Guntur with a diagnosis of thrombotic stroke.
aHUS is a thrombotic microangiopathy caused by mutations of factor H, factor I, factor B, membrane cofactor protein, C3 convertase component, and thrombomodulin gene.
Hydroxyurea, interferon alfa, and peginterferon alfa have been shown to be effective for the prevention of thrombotic complications in patients with PV.
Thrombotic microangiopathy (TMA) often needs detailed investigations to identify the etiology especially in patients who present with multisystem pathology.
Thrombotic microangiopathy (TMA) includes heterogeneous disorders characterized by MAHA, thrombocytopenia, and organ damage due to microvascular occlusion [1].
Thrombotic thrombocytopenic purpura (TTP) is a rare hematological disorder that approved fatal in most cases if not treated properly.
We present a case series of two patients who developed thrombotic thrombocytopenic purpura (TTP) like druginduced thrombotic microangiopathy (DITMA) following the intravenous use of Opana ER.
Akari announced Friday that its lead investigational asset nomacopan, which is currently being evaluated for four indications, has been granted orphan drug designation, or ODD, for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, or HSCT-TMA.
Omeros is preparing to submit a biologics license application, or BLA, and a marketing authorization application, or MAA, to the FDA and to the European Medicines Agency, or EMA, respectively, for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA.
NEW YORK, N.Y., March 13, 2019 -- Akari Therapeutics, Plc (AKTX) announced that it completed a successful Type B, pre-IND meeting with the FDA regarding a proposed clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).